Clinical trials: Phase III
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.
- Trial name
- ADAURA2 (NCT05120349)
- Testing
- Osimertinib
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 390 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week…
- Trial name
- OPTIMIZE (NCT02165826)
- Testing
- Roflumilast, Standard of Care COPD Treatment
- Where
- 2 sites in Slovakia
- Volunteers
- 1,323 people
- Sponsor
- AstraZeneca
Colorectal Adenocarcinoma
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV colorectal adenocarcinoma.
- Trial name
- NCT00034190
- Testing
- S-8184 Paclitaxel Injectable Emulsion
- Where
- Russia
- Volunteers
- 28 people
- Sponsor
- Achieve Life Sciences
Tetanus, Tetanus Vaccine
Phase I/III Clinical Trial of Adsorbed Tetanus Vaccine
The study aimed to evaluate the safety and immunogenicity of an adsorbed tetanus vaccine in healthy individuals between 18 and 43 years of age.
- Trial name
- NCT07740733
- Testing
- Tetanus Toxoid (Adsorbed)
- Where
- China
- Volunteers
- 1,240 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable…
- Trial name
- B-FAST (NCT03178552)
- Testing
- Alectinib, Atezolizumab, Pemetrexed
- Where
- 161 sites in United States, Argentina and 25 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Hemorrhage
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
- Trial name
- NCT02104947
- Testing
- idarucizumab
- Where
- 176 sites in United States, Argentina and 31 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Tetanus, Diphtheria
Confirmatory Study of BK1310 in Healthy Infants
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT03891758
- Testing
- DPT-IPV-Hib, Hib vaccine, DPT-IPV
- Where
- Japan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Hypogonadism
Open-Label Study of ARD-0403 in Testosterone Deficient Men
Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient wellbeing.
- Trial name
- NCT00448955
- Testing
- ARD-0403
- Where
- 12 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ardana Bioscience Ltd
Colorectal Neoplasms
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite…
- Trial name
- RELATIVITY-123 (NCT05328908)
- Testing
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Where
- 139 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
- Trial name
- NCT01422876
- Testing
- high dose FDC, BI 10773 high dose
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,405 people
- Sponsor
- Boehringer Ingelheim
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Male Hypogonadism
Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.
- Trial name
- NCT01403116
- Testing
- Oral testosterone undecanoate, topical testosterone gel
- Where
- 30 sites in United States, Germany
- Volunteers
- 325 people
- Sponsor
- Clarus Therapeutics, Inc.
Asthma
To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study
This is a single blind, single dose, crossover study to investigate the relative efficacy of terbutaline Turbuhaler® 0.4 mg in relation to salbutamol pressurized Metered Dose Inhaler (pMDI) 200 μg in Japanese adult asthmatic…
- Trial name
- NCT01096017
- Testing
- Terbutaline Turbuhaler®, Salbutamol pMDI
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Chronic Hand Eczema
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
The purpose of this trial is to test if delgocitinib cream is effective in treating chronic hand eczema (CHE) and to find out what side effects it may have compared with a cream vehicle with no active medical ingredient in…
- Trial name
- DELTA TEEN (NCT05355818)
- Testing
- Delgocitinib, Cream vehicle
- Where
- 37 sites in Australia, Belgium and 5 more
- Volunteers
- 98 people
- Sponsor
- LEO Pharma
Small Cell Lung Cancer
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT04830813
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Schizophrenia, Autism-Related Irritability
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents
- Trial name
- NCT07424404
- Testing
- KarXT, KarX-EC
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Type 2 Diabetes
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose…
- Trial name
- NCT06290349
- Testing
- DA5221-T1, DA5221-T2, DA5221-B1
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Dong-A ST Co., Ltd.
Paroxysmal Nocturnal Hemoglobinuria
Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment
This trial is a multi-center, single-arm, open-label phase III clinical trial. A total of approximately 35 patients with paroxysmal nocturnal hemoglobinuria who remained anemic despite stable use of C5 complement inhibitor…
- Trial name
- NCT06715943
- Testing
- HRS-5965 capsule
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Anesthesia, Dental
Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures
This Phase 3 clinical study is designed as a multicenter, randomized, blinded, controlled study to evaluate the efficacy, pharmacodynamics, and safety of NV-101 administered as a submucosal injection following completion of a…
- Trial name
- NCT00309335
- Testing
- Phentolamine Mesylate (NV-101)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Novalar Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.